How Could a New Longevity Medicine Create $200B Per Year in Revenue?

What can we learn from an investor who has deployed over $100 million into longevity-focused biotech startups? Alex Colville shares his biggest takeaways, from the importance of founder-market fit to the need to challenge assumptions in a nascent field.